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Introduction: Systemic mastocytosis (SM) with an associated hematological neoplasm (SM-AHN) constitutes about 40% of all patients 
with SM. AHN commonly includes myeloid neoplasms and chronic myelomonocytic leukemia (CMML) is seen in about 30% of these 
patients. Case report: A 67-year-old male presented to hematologist with fatigue and significant weight loss. Abdominal ultrasound 
and computed tomography (CT) detected hepatosplenomegaly, abdominal lymphadenopathy, and ascites. He was anemic with 
leukocytosis and eosinophilia. Trephine biopsy showed > 30% of spindle-shaped mast cells. The KITD816V mutation was present. 
Serum tryptase level was elevated to 62 ng/mL. The patient was diagnosed with aggressive SM and received six cycles of cladribine 
with partial response. Three years later, he developed severe anemia. Eosinophilia and monocytosis (5.6 × 109/L) were demonstrated 
in blood film. Hepatosplenomegaly and abdominal lymphadenopathy were also present. Trephine biopsy did not demonstrate the 
presence of spindle-shaped mast cells, but dysplasia in erythroid and myeloid lineages was evident. The histological result of lymph 
node biopsy as well as blood and bone marrow findings were in line with CMML. He received hydroxyurea, but he transformed soon into 
fatal acute monocytic leukemia. Conclusions: The prognosis of SM-AHN depends on AHN component. Leukemic transformation of AHN 
component may occur in a proportion of patients.
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Introduction
Mastocytosis is a group of rare and heterogeneous disorders resulting 
from the clonal proliferation of abnormal mast cells in extracutaneous 
organs including bone marrow, lymph nodes, spleen, liver, and 
gastrointestinal tract. In the new 2016 WHO classification, mastocytosis 
was removed as one of the subtypes of myeloproliferative neoplasms 
(MPNs) and listed as a separate entity. Mastocytosis may affect people 
at any age, but cutaneous mastocytosis (CM) is usually diagnosed in 
children who present with typical skin features (urticaria pigmentosa). 
Systemic mastocytosis (SM) is commonly seen in adults, and indolent 
(ISM) or advanced (advSM) variants exist. ISM is characterized by 
low mast cell burden, no evidence of “C” findings, or an associated 
hematological neoplasm (AHN). Smoldering SM (SSM) meets the 
criteria of ISM, but it is defined by ≥2 “B” findings, absence of “C” 
findings, or an AHN. Both ISM and SSM have relatively good prognosis. 
Conversely, advSM has more aggressive course and reduced survival, 
and it requires cytoreductive treatment. Advanced SM includes three 
main subtypes, namely, aggressive SM (ASM), SM with an associated 
hematologic neoplasm  (SM-AHN), and mast cell leukemia (MCL). 
Mast cell sarcoma (MCS), one more subtype of SM, occurs extremely 
rare with a localized growth of atypical mast cells especially in the 
larynx, colon, and bone. The prognosis differs between the variants 
with the poorest outcome demonstrated for MCL and MCS [1, 2, 3]. The 
prognosis for SM-AHN varies with the type of AHN [3].
The patients with SM may present the so-called “B” findings 
(benign = organ involvement without its dysfunction) or “C” findings 
(consider cytoreduction = organ damage due to an excessive infiltration 
by neoplastic mast cells). The presence of ≥1 “C” finding is an indication 
for treatment commencement [2]. Detailed characteristics of “B” and 
“C” findings are shown in table I.
The diagnosis of SM requires 1 major plus 1 minor criterion or ≥3 minor 
criteria. The major SM criterion is the presence of mast cell infiltrates 
(>15 cells in aggregates) in bone marrow and/or other extracutaneous 
tissues. Minor SM criteria include: (1) >25% of abnormal mast cells 
in lesion tissue, (2) presence of KITD816V mutation, (3) the aberrant 
expression of CD25 with or without CD2 on neoplastic mast cells, and 
(4) serum tryptase levels >20 ng/mL [1]. The diagnostic algorithm for 
SM is presented in figure 1.
SM is usually diagnosed after the second decade of life. Male and 
female are equally affected. ISM accounts for 46% of all SM cases, 
whereas SM-AHN constitutes 40%, ASM 12%, and MCL 1–2%. 
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Median survivals for above-mentioned variants are 198, 24, 40, and 
2 months, respectively [4].
The clinical and molecular adverse prognostic variables in SM 
have been recently identified. The prognostic model was based 
on a study that included 580 patients with different SM variants. 
The combination of clinical and molecular variables confirmed 
the prognostic significance of the following: (1) mutations within 
the ASXL1, RUNX1, and NRAS genes, (2) advanced SM, (3) 
thrombocytopenia <100 × 109/L, (4) increased alkaline phosphatase, 
and (5) age >60 years [5].
SM-AHN meets the criteria of SM as well as the diagnostic criteria of 
AHN. Of note is that myeloid neoplasms account for majority of the 
reported cases (90%), whereas lymphoid tumors are rarely observed. 
AHN commonly includes myelodysplastic syndromes (MDS), 
Table I. “B” and “C” findings in SM [2]
“B” (benign) findings
1. Bone marrow biopsy with >30% infiltration by mast cells and serum tryptase level >200 ng/mL
2. The presence of features of dysplasia or myeloproliferation in non-mast cell lineage, but criteria for an associated hematological neoplasm not met; blood count 
normal or slightly abnormal
3. Hepatomegaly and/or splenomegaly with normal function and/or lymphadenopathy on physical examination or imaging 
“C” (cytoreduction) findings
1. Bone marrow dysfunction due to mast cell infiltration with cytopenia in at least one line (absolute neutrophil count <1 × 109/L, hemoglobin level <10 g/dL, and 
platelet count <100 × 109/L)
2. Palpable hepatomegaly with liver dysfunction, ascites, and/or portal hypertension
3. Palpable splenomegaly with hypersplenism
4. The presence of large osteolytic lesions with or without pathological fractures
5. Malabsorption with weight loss as a consequence of gastrointestinal mast cell infiltration
Fig. 1. Diagnostic algorithm for SM [3]
AHHN – associated hematological neoplasm; ASM – aggressive systemic mastocytosis; ISM – indolent systemic 
mastocytosis; MCL – mast cell leukemia; SM – systemic mastocytosis; WHO – World Health Organization
1. Bone marrow biopsy with tryptase and CD25 immunohistochemistry
2. Bone marrow aspirate with flow cytometry for the presence of abnormal mast
cells using CD25
3. Molecular study for the presence of the KITD816V mutation using bone
marrow, blood or other involved tissue
4. Serum tryptase level
WHO criteria for SM met
WHO criteria for 
associated hematological 
neoplasm met
WHO criteria for 
associated hematological 
neoplasm not met













Fig. 1. Diagnostic algorithm for SM [3]
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myeloproliferative neoplasms (MPN), chronic myelomonocytic 
leukemia (CMML) and acute myeloid leukemia (AML) [4, 6]. The 
rate of leukemic transformation is more frequent in SM-MDS when 
compared with SM-MPN or SM-CMML [7].
Herein, we report a patient with SM-CMML who achieved partial 
response (PR) after treatment with cladribine (2-CdA), but he 
subsequently progressed into fatal acute monocytic leukemia.
Case report
A 67-year-old male with medical history of chronic gastritis, arterial 
hypertension, and chronic coronary heart disease with severe anemia 
(Hgb <7 g/dL) and leukocytosis with eosinophilia was admitted in July 
2014 to local hospital. He complained of easy fatigue and significant 
weight loss >20 kg within prior 2 months. He had lymphadenopathy 
(biopsy from supraclavicular lymph node was normal) and massive 
splenomegaly on physical examination. Trephine biopsy revealed 
>30% of spindle-shaped mast cells.
On admission to Hematology Unit in May 2015, he presented with 
hepatosplenomegaly, ascites, and peripheral lymphadenopathy. 
His skin was affected with macular rash located on the trunk and 
lower limbs. Abdominal ultrasound and computed tomography 
(CT) scan detected hepatosplenomegaly (liver 19 cm and spleen 
20 cm), abdominal lymphadenopathy (>4 cm), and ascites. He 
was found anemic (Hgb = 9.2 g/dL) with an elevated leukocyte 
count (15 × 109/L) and normal platelet count. Blood film revealed 
eosinophilia (3.4 × 109/L) and single myelocytes and metamyelocytes. 
Monocytosis was not present. Bone marrow aspirate revealed 
eosinophils and single spindle-shaped mast cells (Fig. 2 and 3). The 
flow cytometry study of bone marrow aspirate did not demonstrate 
the presence of abnormal mast cell population. The BCR-ABL, 
JAK2V617F, FIP1L1-PDGFRA, and PDGFRB abnormalities were not 
detected, but the KITD816V mutation was present. Serum tryptase 
level was elevated to 62 ng/ml (normal <11.4 ng/mL). Karyotyping 
and fluorescence in situ hybridization (FISH) were normal. Biopsy of 
the skin revealed the presence of atypical mast cells. The patient was 
diagnosed with ASM and received six cycles of 2-CdA at 0.14 mg/kg/
day for five consecutive days every 6 weeks. As a result, he achieved 
PR according to IWG-MRT/ECNM criteria [8]. The treatment with 
2-CdA was well-tolerated with no grade 3 or 4 hematological and 
non-hematological adverse events. The standard prophylaxis with 
co-trimoxazole and acyclovir was used during the treatment and 
several months thereafter. Three years later, he became deeply 
anemic (Hgb = 4.7 g/dL). Eosinophilia (2.7 × 109/L) and monocytosis 
(5.6 × 109/L) were demonstrated on blood differential test. 
Hepatosplenomegaly and abdominal lymphadenopathy were also 
present. Macular rash was absent. Serum tryptase level was slightly 
elevated (15.1 ng/mL). Trephine biopsy and bone marrow aspirate 
did not demonstrate the presence of spindle-shaped mast cells, but 
monocytosis with dysplastic features in more than 10% of all cells in 
erythroid and myeloid lineages was detected. Eosinophilia in bone 
marrow was still demonstrated (Fig. 4). Flow cytometry did not detect 
increased proportion of blast cells, and the abnormal mast cells were 
also absent. Taken together, the patient fulfilled the criteria for CMML 
[9]. Liver biopsy was unremarkable, but histological examination 
of the excised abdominal lymph node was in line with CMML with 
eosinophilia. Karyotyping was normal and FISH did not reveal the 
presence of 5q31–33 abnormality. The patient received hydroxyurea, 
but he transformed soon into fatal acute monocytic leukemia. He 
expired in a local hospital and autopsy was not performed.
Discussion
SM with an associated hematological neoplasm is the second most 
common subtype of SM after ISM, and CMML remains the second 
most frequent associated myeloid neoplasm. It was demonstrated 
that CMML accounted for 29% of all studied patients among 138 
Fig.2. Predominance of eosinophils in the bone marrow [MGG 
stain 200×]
Fig. 3. Spindle-shaped mast cell [MGG stain 200×]
Fig. 4. Monocytes and eosinophils in the bone marrow [MGG 
stain 200×]
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reported by Mayo Group [7]. The other AHNs included MPN (45%), 
MDS (23%), and AML (3%). The lymphoid neoplasms were very 
rare and included lymphomas and myelomas. There was a single 
case of primary amyloidosis. The rate of leukemic transformation 
was the highest in SM-MDS (29%). The better life expectancy was 
noted for those with SM-MPN. The above findings were in line with 
those presented by other study groups [10, 11]. Of note is that 
5-year survival for SM-AHN was 28% when compared with 61% 
demonstrated for other SM subtypes [10].
The diagnosis of SM component is usually incidental during the 
workup for hematological neoplasm. It should be mentioned that 
the KITD816V mutation was found to be present in pluripotent 
hematopoietic stem cell. However, two clonal neoplasms may exist 
[12].
Most patients with SM-AHN were found to have an elevated serum 
tryptase level and detectable the KITD816V mutation (>90%). The 
frequency of this mutation is dependent on the type of AHN, and 
the highest rate was observed in CMML. It was demonstrated less 
frequently in MPN and AML, and the mutation is not detected in 
lymphoproliferative disorders [13].
Karyotype abnormalities were detected in 32% patients with SM-
AHN but rarely in patients with ASM [14, 15]. The abnormalities were 
most often found in patients with SM-AML [7].
Of note is that the diagnosis of SM-AHN is a challenge. As it was seen 
in our patient, the initial diagnosis of SM was determined based on the 
results of trephine biopsy that was performed to explain the cause of 
splenomegaly. The detection of mast cells in bone marrow prompted 
the further, more detailed diagnostic workup. It should be mentioned 
that mastocytosis is a rare part of the differential diagnosis and can 
be confirmed only after using the appropriate immunohistochemistry 
panel [11]. Interestingly, we did not observe the features typical for 
CMML during patient’s first evaluation—monocytosis was not present 
in both the peripheral blood and bone marrow. Nevertheless, the 
enlarged abdominal lymph nodes were not taken for histopathological 
analysis at that time. It is not excluded that CMML was initially 
presented as an extramedullary manifestation and then progressed 
to leukemic form. Interestingly, eosinophilia was detected since 
first patient’s presentation; however, the FIP1L1–PDGFRA and 
PDGFRB rearrangements were not found. It was demonstrated that 
the presence of eosinophilia in SM (except cases with the FIP1L1–
PDGFRA gene fusion) has negative prognostic significance and 
may reduce event-free and overall survivals when compared with 
SM without eosinophilia [16]. The prominent eosinophilia is seen in 
about 34% of patients with SM-AHN, most commonly in patients with 
SM-MPN (56%). The latter includes chronic eosinophilic leukemia in 
48% of patients. The clinical outcome of SM-MPN with and without 
eosinophilia is similar; however, those with the FIP1L1–PDGFRA 
transcript usually respond to imatinib mesylate [7].
The modern treatment of advanced SM should start with small 
molecule kinase inhibitor–midostaurin which has in vitro activity 
against kinase domain KIT mutation. Midostaurin (Rydapt) was 
approved by the U.S. Food and Drug Administration (FDA) for 
AdvSM in 2017; however, it is not reimbursed in Poland. Eighty-nine 
SM patients received midostaurin at a dose of 100 mg twice daily with 
the overall response rate (ORR) of 60% [17]. Several study groups 
presented their data on efficacy and safety of 2-CdA which remained 
a treatment of choice before midostaurin era. Ten patients with SM 
received 2-CdA and all patients responded to treatment; however, 
the response took several months and was incomplete and transient 
[18]. The largest series on 2-CdA in mastocytosis was presented 
by Barete et al. [19]. The study included 68 patients and the ORR 
was 50% for those with advanced disease (ASM 43% and SM-AHN 
59%). Our patient responded to 2-CdA treatment and remained in 
PR for almost 3 years. The treatment was well-tolerated with no 
severe adverse events. Our small analysis of nine patients with 
advSM treated with 2-CdA has shown 60% ORR, but none of the 
patients achieved complete remission (unpublished data). The other 
therapeutic options for advSM include both standard and pegylated 
interferon-a. Imatinib mesylate is FDA-approved for the treatment 
of adult patients with ASM without the KITD816V mutation or with 
unknown KIT mutational status. The only curative option remains 
allogeneic stem cell transplantation [20].
Transformation into acute leukemia is not a rare event in patients 
with SM-AHN. The rate of transformation is found to be 13% in a 
large study by Mayo Group; however, only 6% of patients progressed 
from CMML category. Almost 30% of SM-MDS patients had leukemic 
transformation [7]. The treatment for leukemic transformation is 
unsuccessful with significantly reduced survival as it was seen in our 
case. In total, two out of nine patients from our cohort progressed into 
acute leukemia (1 SM-MDS and 1 SM-CMML) (data not published).
Conclusions
Diagnosis of SM-AHN is difficult and may require cooperation with 
other specialists when the symptoms of mast cell activation occur. 
The prognosis depends on AHN component. 2-CdA still remains a 
mainstay of treatment in Poland as midostaurin is not reimbursed. 
Leukemic transformation of AHN component occurs in a proportion 
of patients and has negative impact on survival.
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